Immune thrombocytopenia (ITP) is a bleeding disorder in which there is a shortage of platelets, the blood cells responsible for clotting, according to MedlinePlus. The condition typically results when ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

DEAR DR. ROACH: What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and after lab results showed a low blood platelet count, I ...

SAN DIEGO -- Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...

Immune thrombocytopenia (ITP) is a rare condition that causes a low platelet count. People with ITP can experience life threatening bleeding if the condition is not treated. Many people with ITP go ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

Dear Dr. Roach: What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and after lab results showed a low blood platelet count, I ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first ...